To Present Data in October

ReNeuron Group plc
09 October 2006




                              PRESS RELEASE

     ReNeuron to Present at American Neurological Association Conference

-Results to Form Part of Data Package to the US FDA In Support of Application to
                     Commence Clinical Studies with ReN001-


Guildford, UK, 9 October 2006: ReNeuron Group plc (LSE: RENE.L) today announces
that it will present key pre-clinical efficacy data regarding its ReN001 stem
cell therapy for stroke at the 131st Annual Meeting of the American Neurological
Association in Chicago, US on October 8-11.  The poster presentation will
describe the positive and dose dependent effects of ReN001 in a pre-clinical
rodent model of chronic stroke disability.

The results of the studies demonstrate that higher doses of clinical-grade
ReN001 stem cells have the potential to reverse both the sensory and motor
symptoms associated with stroke disability.  These results will form part of the
Company's data package in support of its impending application to the US FDA to
commence initial clinical studies with ReN001.

More information about the conference may be found at www.aneuroa.org.


Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer                 Tel: [phone]
John Sinden, Chief Scientific Officer

Financial Dynamics
David Yates                                          Tel: [phone]
Sarah Macleod


Notes to Editors

ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.

The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  The Company plans to file for approval to
commence a Phase I clinical study in stroke by the end of 2006, with the study
commencing as soon as possible thereafter.   There are an estimated 50 million1
stroke survivors worldwide, approximately half of which are left with permanent
disabilities.  The healthcare costs of caring for these patients is estimated to
amount to $45 billion2 in the US alone.

The Group has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a genetic and fatal neurodegenerative
disorder that affects around 1 in 10,000 people.  This programme is in
pre-clinical development.

In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.


 1. MOSES (Morbidity and mortality after stroke - Eprosartan vs nitrendipine for
    secondary prevention) study, Feb 2006
 2. American Heart Association, Reporting Standards for Carotid Artery
    Angioplasty and Stent Placement, (Stroke, 2004; 35:e112).

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange                 AIIR